ClinicalTrials.gg
RecruitingNCT07023614FORTITUDE-HCMUpdated Oct 26, 2026

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A Phase 2 interventional study of Ninerafaxstat 200mg MR and Placebo in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Imbria Pharmaceuticals, Inc.. Recruiting at 76 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Imbria Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 26, 2026Site recruiting status changed9 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Cardiomyopathy, Hypertrophic with a site in United States — 23 open to participants now, 37 under way, 6 of them phase 3. Cardiomyopathy, Hypertrophic · United States.

Planned enrollment
17th of 65
165 · median 50
Started
2025
with 6 others
Phase 2
21 of 125
3 open now
Primary completion
2026-12
later than 11 of 36 live
Registered
114th of 125
by date
Lead sponsor
2 of 125
Imbria Pharmaceuticals, Inc.

Among the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, this one is the 17th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 11 of the 36 other live ones, and was the 114th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

23 of the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, or all of them as a file.
02

Study summary

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM

03

Conditions studied

  • Non-obstructive Hypertrophic Cardiomyopathy

Keywords

  • nHCM
  • non-obstructive HCM
  • non-obstructive hypertrophic cardiomyopathy
  • HCM
  • hypertrophic cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  • Has a clinical diagnosis of HCM consistent with current American College of Cardiology/American Heart Association and European Society of Cardiology Guideline definitions
  • Has had confirmation of nHCM by the echocardiography core laboratory based on screening rest and exercise stress echocardiography
  • (NYHA) functional Class II or III at screening
  • Functional limitation as defined by a screening CPET

Select Exclusion Criteria:

  • Has a known or suspected infiltrative, genetic, or storage disorder causing cardiac hypertrophy that mimics nHCM
  • Has any other condition judged by the investigator to be the primary cause of dyspnea, exercise intolerance, and/or angina
  • Has an inability to exercise on a treadmill or bicycle (eg, orthopedic limitations)
  • Has any medical condition that precludes upright exercise stress testing

Other protocol-defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Ninerafaxstat

    Drug: Ninerafaxstat 200mg MR

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Ninerafaxstat 200mg Modified Release tablet administered BID

  • DrugPlacebo

    Matching placebo tablet administered BID

06

What researchers measure

Primary outcomes

  1. Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)

    The Clinical Summary Score is a merging of symptom frequency and symptom burden domains into a total symptom score combined with the physical limitation domain. Scoring ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in ventilatory efficiency (VE/VCO2 slope) during cardiopulmonary exercise testing (CPET)

    Time frame: Baseline to Week 12

  2. Change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)

    The Total Symptom Score is a merging of symptom frequency and symptom burden domains. Scoring ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline to Week 12

  3. Change in the Kansas City Cardiomyopathy Questionnaire Physical Limitations Score (KCCQ-PLS)

    The Physical Limitations Score is a single-domain score. Scoring ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline to Week 12

  4. Change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS)

    The Overall Summary Score is a merging of symptom, physical limitations, social limitations, and quality of life domains. Scoring ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline to Week 12

07

Study locations

63 of 76 sites recruiting
  • Imbria Investigational Site
    La Jolla, California 92037, United States
    Recruiting
    • Study Coordinator · Contact858-246-5640
  • Imbria Investigational Site
    Los Angeles, California 90048, United States
    Recruiting
    • Study Coordinator · Contact6264094913
  • Imbria Investigational Site
    San Francisco, California 94143, United States
    Recruiting
  • Imbria Investigational Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Study Coordinator · Contact202-877-6334
  • Imbria Investigational Site
    Miami, Florida 33136, United States
    Recruiting
    • Study Coordinator · Contact7865785926
  • Imbria Investigational Site
    Atlanta, Georgia 30322, United States
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Chicago, Illinois 60611, United States
    Recruiting
    • Study Coordinator · Contact312-695-4067
    • Study Coordinator · Contact312-926-8629
  • Imbria Investigational Site
    Oak Lawn, Illinois 60453, United States
    Not yet recruiting
    • Study Coordinator · Contact708.684.5137
  • Imbria Investigational Site
    Baltimore, Maryland 21218, United States
    Recruiting
    • Study Coordinator · Contact
    • · Contact44327891702
  • Imbria Investigational Site
    Boston, Massachusetts 02114, United States
    Recruiting
    • Study Coordinator · Contact203-450-8273
  • Imbria Investigational Site
    Burlington, Massachusetts 01805, United States
    Recruiting
    • Study Coordinator · Contact781-825-8658
  • Imbria Investigational Site
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • Study Coordinator · Contact6163910284
  • Imbria Investigational Site
    Rochester, Minnesota 55905, United States
    Recruiting
    • Study Coordinator · Contact5072844253
  • Imbria Investigational Site
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact314-362-1962
  • Imbria Investigational Site
    New York, New York 10016, United States
    Recruiting
    • Study Coordinator · Contact6465010568
  • Imbria Investigational Site
    New York, New York 10032, United States
    Not yet recruiting
    • Study Coordinator · Contact(212) 305-1368
  • Imbria Investigational Site
    Charlotte, North Carolina 28204, United States
    Recruiting
    • Study Coordinator · Contact7043554796
  • Imbria Investigational Site
    Portland, Oregon 97239, United States
    Recruiting
    • Study Coordinator · Contact5034948799
  • Imbria Investigational Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact2156623768
  • Imbria Investigational Site
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Study Coordinator · Contact(215) 503-4913
  • Imbria Investigational Site
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact7134414960
  • Imbria Investigational Site
    Houston, Texas 77030, United States
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Plano, Texas 75093, United States
    Recruiting
    • Study Coordinator · Contact4698144853
  • Imbria Investigational Site
    Salt Lake City, Utah 84132-0001, United States
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Study Coordinator · Contact434-982-1058
  • Imbria Investigational Site
    Richmond, Virginia 23298, United States
    Recruiting
    • Study Coordinator · Contact8048281601
  • Imbria Investigational Site
    Milwaukee, Wisconsin 53215, United States
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Graz, 8036, Austria
    Recruiting
    • Study Coordinator · Contact4331638580264
  • Imbria Investigational Site
    Edegem, 2650, Belgium
    Recruiting
    • Study Coordinator · Contact3238213000
  • Imbria Investigational Site
    Montpellier, 34295, France
    Recruiting
    • Study Coordinator · Contact+33 467 336 431
  • Imbria Investigational Site
    Paris, 75015, France
    Recruiting
    • Study Coordinator · Contact33 1 56 09 27 27
  • Imbria Investigational Site
    Saint-Herblain, 44800, France
    Recruiting
    • Study Coordinator · Contact+33 240 165 710
  • Imbria Investigational Site
    Bad Oeynhausen, 32545, Germany
    Recruiting
    • Study Coordinator · Contact495731973399
  • Imbria Investigational Site
    Göttingen, 37075, Germany
    Recruiting
    • Study Coordinator · Contact4905513962720
  • Imbria Investigational Site
    Heidelberg, 69120, Germany
    Recruiting
    • Study Coordinator · Contact4962215638336
  • Imbria Investigational Site
    Jena, 07747, Germany
    Not yet recruiting
    • Study Coordinator · Contact4915232184941
  • Imbria Investigational Site
    Bologna, 40138, Italy
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Florence, 50139, Italy
    Recruiting
    • Study Coordinator · Contact390557945138
  • Imbria Investigational Site
    Massa, 54100, Italy
    Recruiting
    • Study Coordinator · Contact393277861790
  • Imbria Investigational Site
    Milan, 20131, Italy
    Recruiting
    • Study Coordinator · Contact390264447940
  • Imbria Investigational Site
    Milan, 20146, Italy
    Recruiting
    • Study Coordinator · Contact+39 02619112895
  • Imbria Investigational Site
    Milan, 20162, Italy
    Recruiting
    • Study Coordinator · Contact+39 0264446715
  • Imbria Investigational Site
    Naples, 80131, Italy
    Recruiting
    • Study Coordinator · Contact+39 3357621204
  • Imbria Investigational Site
    Amsterdam-Zuidoost, 1105 AZ, Netherlands
    Recruiting
    • Study Coordinator · Contact310204444912
  • Imbria Investigational Site
    Leiden, 2333ZC, Netherlands
    Not yet recruiting
    • Study Coordinator · Contact31715263009
  • Imbria Investigational Site
    Nijmegen, 6525 GA, Netherlands
    Not yet recruiting
    • Study Coordinator · Contact31243616785
  • Imbria Investigational Site
    Rotterdam, 3015 AA, Netherlands
    Recruiting
    • Study Coordinator · Contact+31 10 704 0 704
  • Imbria Investigational Site
    Katowice, 40-555, Poland
    Recruiting
    • Study Coordinator · Contact+48 604 122 669
  • Imbria Investigational Site
    Warsaw, 02-507, Poland
    Recruiting
    • Study Coordinator · Contact48227221113
  • Imbria Investigational Site
    Wroclaw, 53-114, Poland
    Recruiting
    • Study Coordinator · Contact48 517 311 583
  • Imbria Investigational Site
    Guimarães, 4835-044, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Lisbon, 1169-024, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Lisbon, 1500-650, Portugal
    Recruiting
    • Study Coordinator · Contact351969870409
  • Imbria Investigational Site
    Lisbon, 1998-018, Portugal
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34 677 381 128
  • Imbria Investigational Site
    A Coruña, Galicia 15006, Spain
    Recruiting
    • Study Coordinator · Contact+34 981 176 540
  • Imbria Investigational Site
    Madrid, Madrid 28034, Spain
    Recruiting
    • Study Coordinator · Contact34 913 368 954
  • Imbria Investigational Site
    Vigo, Pontevedra 36312, Spain
    Recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Seville, Sevilla 41009, Spain
    Recruiting
    • Study Coordinator · Contact34 600 162 398
  • Imbria Investigational Site
    Seville, Sevilla 41013, Spain
    Recruiting
    • Study Coordinator · Contact+34 955 013 105
  • Imbria Investigational Site
    Barcelona, 8036, Spain
    Recruiting
    • Study Coordinator · Contact3463329611
  • Imbria Investigational Site
    Barcelona, 8041, Spain
    Recruiting
    • Study Coordinator · Contact3493291900
  • Imbria Investigational Site
    Barcelona, 8907, Spain
    Recruiting
    • Study Coordinator · Contact9326073202108
  • Imbria Investigational Site
    El Palmar, 30120, Spain
    Recruiting
    • Study Coordinator · Contact34689931292
  • Imbria Investigational Site
    Granada, 18014, Spain
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Madrid, 28046, Spain
    Not yet recruiting
    • Study Coordinator · Contact
  • Imbria Investigational Site
    Madrid, 28222, Spain
    Recruiting
    • Study Coordinator · Contact34911917297
  • Imbria Investigational Site
    Palma de Mallorca, 07198, Spain
    Recruiting
    • Study Coordinator · Contact34871202102
  • Imbria Investigational Site
    Salamanca, 37007, Spain
    Recruiting
    • Study Coordinator · Contact34658403315
  • Imbria Investigational Site
    Valencia, 03010, Spain
    Recruiting
    • Study Coordinator · Contact34965913678
  • Imbria Investigational Site
    Valencia, 46026, Spain
    Recruiting
    • Study Coordinator · Contact34965913921
  • Imbria Investigational Site
    London, England W12 0HS, United Kingdom
    Recruiting
    • Study Coordinator · Contact44 020 3313 7156
  • Imbria Investigational Site
    Glasgow, Scotland G51 4TF, United Kingdom
    Recruiting
    • Study Coordinator · Contact44-141 232 7600
  • Imbria Investigational Site
    London, EC1A 7BE, United Kingdom
    Recruiting
    • Study Coordinator · Contact442037658635
  • Imbria Investigational Site
    London, SW3 6HP, United Kingdom
    Recruiting
    • Study Coordinator · Contact4403301288121
  • Imbria Investigational Site
    Oxford, OX3 9DU, United Kingdom
    Recruiting
    • Study Coordinator · Contact441865234554
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added. Imbria Investigational Site is now Not yet recruiting
Show 9 added (5 United States, 2 Spain, 1 Italy, 1 Portugal)
  • Imbria Investigational Site · Atlanta, United States
  • Imbria Investigational Site · New York, United States
  • Imbria Investigational Site · Houston, United States
  • Imbria Investigational Site · Salt Lake City, United States
  • Imbria Investigational Site · Milwaukee, United States
  • Imbria Investigational Site · Bologna, Italy
  • Imbria Investigational Site · Lisbon, Portugal
  • Imbria Investigational Site · Granada, Spain
  • Imbria Investigational Site · Madrid, Spain
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Imbria Investigational Site · Madrid, SpainContact •••7297→none listed
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    9 sites added. Imbria Investigational Site is now Not yet recruiting
    Show 9 added (5 United States, 2 Spain, 1 Italy, 1 Portugal)
    • Imbria Investigational Site · Atlanta, United States
    • Imbria Investigational Site · New York, United States
    • Imbria Investigational Site · Houston, United States
    • Imbria Investigational Site · Salt Lake City, United States
    • Imbria Investigational Site · Milwaukee, United States
    • Imbria Investigational Site · Bologna, Italy
    • Imbria Investigational Site · Lisbon, Portugal
    • Imbria Investigational Site · Granada, Spain
    • Imbria Investigational Site · Madrid, Spain
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Imbria Investigational Site · Madrid, SpainContact •••7297→none listed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07023614
Lead sponsor
Imbria Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Oct 6, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Medical Monitor
Contact
info@imbria.com
(617) 675-4060

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ninerafaxstat

Start the discussion